Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2016-02-702761 http://scihub22266oqcxt.onion/10.1182/blood-2016-02-702761 C5161010!5161010!27252232     free     free     free       Blood 2016 ; 128 (3): 331-6 Nephropedia Template TP {{tp|p=27252232|t=2016. Idelalisib in the management of lymphoma |pdf=|usr=}}{{27252232}} gab.com Text Idelalisib in the management of lymphoma JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=27252232 #FOAvip Inhibition of the phosphatidylinositol-3-kinase (PI3K) pathway as an anticancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3K? inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide a brief summary of the preclinical data, and describe the clinical experience with this agent in patients with lymphoma. We describe some of the idiosyncratic toxicities of this agent, some of the mechanisms of resistance, and some of the ongoing combination strategies. Twit Text FOAVip Idelalisib in the management of lymphoma ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=27252232 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27252232 #FOAvip English Wikipedia <ref>{{Cite pmid|27252232}}</ref> Idelalisib in the management of lymphoma #MMPMID27252232 Cheah CY; Fowler NH Blood 2016[Jul]; 128 (3): 331-6 PMID27252232show ga Inhibition of the phosphatidylinositol-3-kinase (PI3K) pathway as an anticancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3K? inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide a brief summary of the preclinical data, and describe the clinical experience with this agent in patients with lymphoma. We describe some of the idiosyncratic toxicities of this agent, some of the mechanisms of resistance, and some of the ongoing combination strategies. äIdelalisib in the management of lymphoma (epmc).pdf DeepDyve Pubget Overpricing